Barry I Hudson1, Hannah Gardener2, Wen Liu-Mares3, Chuanhui Dong2, Ken Cheung4, Mitchell S V Elkind5, Clinton B Wright6, Ralph L Sacco7, Tatjana Rundek8. 1. Division of Endocrinology, Diabetes & Metabolism, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. 2. Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. 3. Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. 4. Department of Biostatistics, Mailman Public School of Health, Columbia University, New York, NY, USA. 5. Stroke Division, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman Public School of Health, Columbia University, New York, NY, USA. 6. Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Neuroscience Program, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. 7. Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. 8. Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Abstract
BACKGROUND: Recent cohort studies suggested that serum levels of soluble Receptor for Advanced Glycation End-products (sRAGE) are associated with the risk of cardiovascular disease. We hypothesized that sRAGE levels are associated with subclinical atherosclerosis in a racially and ethnically diverse population. METHODS AND RESULTS: 828 stroke-free participants from the Northern Manhattan Study (mean age 71.1±8.7yrs; 64% Hispanic, 19% black, and 17% white) underwent high-resolution carotid B-mode ultrasound to measure carotid plaque (present in 62% of subjects) and intima-media thickness (IMT) (mean Total=0.96±0.10 mm). Serum sRAGE was measured by ELISA and associations tested between sRAGE with IMT and plaque presence. Soluble RAGE levels were not associated with plaque presence or IMT after adjusting for sociodemographic, vascular risk factors and medication use. Stratification by race-ethnicity did not reveal any associations with carotid IMT or plaque. CONCLUSION: In the present study, sRAGE levels were not associated with carotid atherosclerosis.
BACKGROUND: Recent cohort studies suggested that serum levels of soluble Receptor for Advanced Glycation End-products (sRAGE) are associated with the risk of cardiovascular disease. We hypothesized that sRAGE levels are associated with subclinical atherosclerosis in a racially and ethnically diverse population. METHODS AND RESULTS: 828 stroke-free participants from the Northern Manhattan Study (mean age 71.1±8.7yrs; 64% Hispanic, 19% black, and 17% white) underwent high-resolution carotid B-mode ultrasound to measure carotid plaque (present in 62% of subjects) and intima-media thickness (IMT) (mean Total=0.96±0.10 mm). Serum sRAGE was measured by ELISA and associations tested between sRAGE with IMT and plaque presence. Soluble RAGE levels were not associated with plaque presence or IMT after adjusting for sociodemographic, vascular risk factors and medication use. Stratification by race-ethnicity did not reveal any associations with carotid IMT or plaque. CONCLUSION: In the present study, sRAGE levels were not associated with carotid atherosclerosis.
Authors: Sergio Raposeiras-Roubín; Bruno K Rodiño-Janeiro; Lilian Grigorian-Shamagian; María Moure-González; Ana Seoane-Blanco; Alfonso Varela-Román; Ezequiel Alvarez; José R González-Juanatey Journal: Eur J Heart Fail Date: 2010-08-03 Impact factor: 15.534
Authors: Ling Yan; Per Bjork; Radu Butuc; Joseph Gawdzik; Judy Earley; Gene Kim; Marion A Hofmann Bowman Journal: Atherosclerosis Date: 2013-02-28 Impact factor: 5.162
Authors: Evis Harja; De-xiu Bu; Barry I Hudson; Jong Sun Chang; Xiaoping Shen; Kellie Hallam; Anastasia Z Kalea; Yan Lu; Rosa H Rosario; Sai Oruganti; Zana Nikolla; Dmitri Belov; Evanthia Lalla; Ravichandran Ramasamy; Shi Fang Yan; Ann Marie Schmidt Journal: J Clin Invest Date: 2008-01 Impact factor: 14.808
Authors: Christine Koulis; Peter Kanellakis; Raelene J Pickering; Despina Tsorotes; Andrew J Murphy; Stephen P Gray; Merlin C Thomas; Karin A M Jandeleit-Dahm; Mark E Cooper; Terri J Allen Journal: Clin Sci (Lond) Date: 2014-10 Impact factor: 6.124
Authors: Jason B Lindsey; James A de Lemos; Francesco Cipollone; Colby R Ayers; Anand Rohatgi; David A Morrow; Amit Khera; Darren K McGuire Journal: Diabetes Care Date: 2009-04-14 Impact factor: 19.112
Authors: Per M Humpert; Zdenka Djuric; Stefan Kopf; Gottfried Rudofsky; Michael Morcos; Peter P Nawroth; Angelika Bierhaus Journal: Cardiovasc Diabetol Date: 2007-03-07 Impact factor: 9.951
Authors: S Goya Wannamethee; Paul Welsh; Olia Papacosta; Elizabeth A Ellins; Julian P J Halcox; Peter H Whincup; Naveed Sattar Journal: Atherosclerosis Date: 2017-07-12 Impact factor: 5.162